Thursday, September 07, 2017 8:20:08 AM
Posted by Jennifer Salazar
Mesoblast limited
Maxim Group set a $14.00 target price on Mesoblast limited (NASDAQ:MESO) in a research note issued to investors on Wednesday. The firm currently has a buy rating on the stock.
Mesoblast reported year-end (FYE June 30) with a net loss of $77M and ended the period with $46M in cash. The company completed a $40M raise on August 29, 2017 and currently has $84M in cash on the balance sheet the firm’s analyst commented.
Several other equities research analysts have also issued reports on the stock. Cantor Fitzgerald reiterated a buy rating on shares of Mesoblast limited in a research note on Wednesday. BidaskClub lowered shares of Mesoblast limited from a sell rating to a strong sell rating in a research note on Friday, July 28th. Credit Suisse Group set a $11.00 price target on shares of Mesoblast limited and gave the company a hold rating in a research note on Tuesday, July 18th. Finally, Zacks Investment Research upgraded shares of Mesoblast limited from a sell rating to a hold rating in a research note on Saturday, June 24th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of Hold and a consensus target price of $12.70.
Mesoblast limited (NASDAQ MESO) opened at 6.24 on Wednesday. The company has a 50-day moving average price of $7.20 and a 200-day moving average price of $8.23. The firm’s market cap is $529.68 million. Mesoblast limited has a one year low of $4.01 and a one year high of $12.50.
A hedge fund recently raised its stake in Mesoblast limited stock. Princeton Capital Management Inc. boosted its stake in Mesoblast limited (NASDAQ:MESO) by 15.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 155,700 shares of the company’s stock after buying an additional 20,945 shares during the period. Princeton Capital Management Inc. owned about 0.20% of Mesoblast limited worth $1,398,000 at the end of the most recent quarter. 2.95% of the stock is currently owned by hedge funds and other institutional investors.
Recent MESO News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/29/2024 11:14:45 AM
- Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024 • GlobeNewswire Inc. • 08/28/2024 11:27:43 PM
- Mesoblast Financial Results and Corporate Update Webcast • GlobeNewswire Inc. • 08/27/2024 11:25:57 PM
- Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024 • GlobeNewswire Inc. • 07/31/2024 01:13:29 AM
- FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) • GlobeNewswire Inc. • 07/23/2024 11:53:49 AM
- Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain • GlobeNewswire Inc. • 07/22/2024 12:45:12 AM
- Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) • GlobeNewswire Inc. • 07/09/2024 12:37:09 AM
- Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week • GlobeNewswire Inc. • 07/01/2024 05:55:36 AM
- Mesoblast Corporate Presentation at Investor Conference • GlobeNewswire Inc. • 06/03/2024 12:23:37 AM
- Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024 • GlobeNewswire Inc. • 04/30/2024 01:05:17 AM
- FDA Commentary Sends Biotech Soaring During Premarket Hours • AllPennyStocks.com • 03/26/2024 01:25:00 PM
- United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) • GlobeNewswire Inc. • 03/26/2024 02:34:20 AM
- Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer • GlobeNewswire Inc. • 03/13/2024 11:30:47 PM
- United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD) • GlobeNewswire Inc. • 03/10/2024 11:54:12 PM
- Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023 • GlobeNewswire Inc. • 02/28/2024 10:57:09 PM
- Mesoblast Financial Results and Corporate Update Webcast • GlobeNewswire Inc. • 02/26/2024 12:00:00 PM
- United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease • GlobeNewswire Inc. • 02/15/2024 12:46:40 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/01/2024 02:34:30 AM
- Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023 • GlobeNewswire Inc. • 01/31/2024 02:13:34 AM
- Mesoblast Gets FDA's Special Pediatric Designation for Revascor Heart Treatment • Dow Jones News • 01/19/2024 12:28:00 AM
- United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease • GlobeNewswire Inc. • 01/18/2024 11:36:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/16/2024 11:33:54 AM
- Form F-6 POS - Post-effective amendments for immediately effective filing • Edgar (US Regulatory) • 01/05/2024 02:57:09 AM
- Form F-6 POS - Post-effective amendments for immediately effective filing • Edgar (US Regulatory) • 12/22/2023 10:13:02 PM
- Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease • GlobeNewswire Inc. • 11/26/2023 11:56:21 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM